Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
From Screening to Treatment: Technology’s Impact on Breast Cancer Care
share announcement

From Screening to Treatment: Technology’s Impact on Breast Cancer Care

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Breast Cancer".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 5775

Special Issue Editor

Dr. Jaroslaw Skokowski

E-Mail Website
Guest Editor
1. Department of Medicine, Academy of Applied Medical and Social Sciences, Akademia Medycznych I Spolecznych Nauk Stosowanych (AMiSNS), 2 Lotnicza Street, 82-300 Elbląg, Poland
2. Department of General Surgery and Surgical Oncology, “Saint Wojciech” Hospital, “Nicolaus Copernicus” Health Center, Jana Pawła II 50, 80-462 Gdańsk, Poland
Interests: breast cancer surgery; artificial intelligence; virtual reality in surgery

Special Issue Information

Dear Colleagues,

This Special Issue will uncover the transformative impact of new technologies, virtual reality (VR), and artificial intelligence (AI) across the development of breast cancer care. It will explore advancements in screening methods such as digital mammography and AI-powered image interpretation, alongside diagnostic innovations including AI-driven biopsy guidance and personalized risk stratification. Histopathological improvements through digital pathology and AI-enabled image analysis will be discussed, as well as surgical interventions enhanced by augmented reality (AR) and robotics. Additionally, the role of AI and AR in elucidating genetic and environmental risk factors for breast cancer will be explored. These innovations aim to optimize treatment strategies, from radiotherapy planning to targeted drug delivery, ultimately opening up a new era of precision oncology and personalized patient care. Ethical considerations regarding data privacy and equity will also be addressed, highlighting the need for collaborative efforts to navigate the ethical and societal implications of these advancements. Additionally, this Special Issue will highlight the collaborative efforts of diverse specialties, emphasizing a transdisciplinary approach to address the multifaceted challenges of breast cancer. By integrating cutting-edge technologies and fostering interdisciplinary collaboration, this Special Issue will pave the way for a comprehensive and patient-centered approach to breast cancer management.

I look forward to hearing from you.

Dr. Jaroslaw Skokowski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Dr. Jaroslaw Skokowski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • technology
  • artificial intelligence (AI)
  • virtual reality (VR)
  • screening
  • diagnosis
  • digital pathology
  • robotic mastectomy
  • precision oncology
  • transdisciplinary collaboration

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

14 pages, 1383 KiB  
Article
Effects of Immersive Virtual Therapy as a Method Supporting the Psychological and Physical Well-Being of Women with a Breast Cancer Diagnosis: A Randomized Controlled Trial
by Oliver Czech, Aleksandra Kowaluk, Tomasz Ściepuro, Katarzyna Siewierska, Jakub Skórniak, Rafał Matkowski and Iwona Malicka
Curr. Oncol. 2024, 31(10), 6419-6432; https://doi.org/10.3390/curroncol31100477 - 21 Oct 2024
Viewed by 775
Abstract
This study aimed to evaluate the effectiveness of virtual reality (VR) in the mental state and quality of sleep improvement and physical activity (PA) increase of patients diagnosed with breast cancer (BC). A total of 33 subjects divided into experimental (EG, n = [...] Read more.
This study aimed to evaluate the effectiveness of virtual reality (VR) in the mental state and quality of sleep improvement and physical activity (PA) increase of patients diagnosed with breast cancer (BC). A total of 33 subjects divided into experimental (EG, n = 17) and control (CG, n = 16) groups were assessed with the Mental Adjustment to Cancer Scale (Mini-MAC), International Physical Activity Questionnaire (IPAQ), Pittsburgh Sleep Quality Index (PSQI), and the Modified Hospital Anxiety and Depression Scale (HADS-M) at four time points. The experimental intervention consisted of eight VR TierOne sessions. Significant differences favoring the EG were identified in the group x time interactions for the main outcomes: destructive style of coping with the disease (p < 0.001), walking (p = 0.04), moderate (p < 0.001) and overall activity (p = 0.004), quality of sleep (p < 0.001), depressive symptoms (p < 0.001), anxiety levels (p < 0.001), aggression levels (p = 0.002), and overall HADS (p < 0.001). Trends, favoring the EG, in the constructive style of coping, sedentary behavior and intensive PA, and sleep efficiency and sleeping time were also found. A VR intervention improves general well-being in terms of the measured parameters. Full article
(This article belongs to the Special Issue From Screening to Treatment: Technology’s Impact on Breast Cancer Care)
►▼ Show Figures

Figure 1

10 pages, 228 KiB  
Article
A Retrospective Analysis of Diagnostic Breast Imaging Outcomes in Young Women at a Tertiary Care Center
by Navdeep Dehar, Doris Jabs, Wilma Hopman and Mihaela Mates
Curr. Oncol. 2024, 31(7), 3939-3948; https://doi.org/10.3390/curroncol31070291 - 6 Jul 2024
Cited by 1 | Viewed by 1086
Abstract
(1) Purpose: The purpose of this study was to describe the outcomes of diagnostic breast imaging and the incidence of delayed breast cancer diagnosis in the study population. (2) Methods: We collected the outcome data from diagnostic mammograms and/or breast ultrasounds (USs) performed [...] Read more.
(1) Purpose: The purpose of this study was to describe the outcomes of diagnostic breast imaging and the incidence of delayed breast cancer diagnosis in the study population. (2) Methods: We collected the outcome data from diagnostic mammograms and/or breast ultrasounds (USs) performed on women between the ages of 30 and 50 with symptomatic breast clinical presentations between 2018 and 2019. (3) Results: Out of 171 eligible patients, 10 patients (5.8%) had BIRADS 0, 90 patients (52.6%) had benign findings (BIRADS 1 and 2), 41 (24.0%) patients had probable benign findings requiring short-term follow-up (BIRADS 3), while 30 (17.5%) patients had findings suspicious of malignancy (BIRADS 4 and 5). In the BIRADS 3 group, 92.7% had recommended follow-up, while in BIRADS 4 and 5, only 83.3% underwent recommended biopsy at a mean time of 1.7 weeks (range 0–22 wks) from their follow-up scan. Ten (6%) patients were diagnosed with breast cancer, all of whom had BIRADS 4 or 5, with a mean time of breast cancer diagnosis from initial diagnostic imaging of 2.2 weeks (range 1–22 wks). No patients had delayed breast cancer diagnosis in our cohort. (4) Conclusions: We conclude that diagnostic mammograms and breast US are appropriate investigations for clinical breast concerns in women aged 30–50 years. Full article
(This article belongs to the Special Issue From Screening to Treatment: Technology’s Impact on Breast Cancer Care)

Review

Jump to: Research, Other

14 pages, 1246 KiB  
Review
Clinical Pharmacist-Led Interventions for Improving Breast Cancer Management—A Scoping Review
by Radiana Staynova, Evelina Gavazova and Daniela Kafalova
Curr. Oncol. 2024, 31(8), 4178-4191; https://doi.org/10.3390/curroncol31080312 - 25 Jul 2024
Viewed by 1935
Abstract
Breast cancer is the leading cause of cancer-related death in women worldwide and the fifth most common cause of cancer death overall. Most women with breast cancer have a good prognosis if the cancer is detected at an early stage and the patients [...] Read more.
Breast cancer is the leading cause of cancer-related death in women worldwide and the fifth most common cause of cancer death overall. Most women with breast cancer have a good prognosis if the cancer is detected at an early stage and the patients have access to the appropriate treatment and disease management. This study aims to evaluate the impact of pharmacist-led interventions on breast cancer management and health outcomes. A literature review was carried out through the scientific databases PubMed, Scopus, and Web of Science using predefined keywords. Only full-text original articles written in English that investigated the role of the pharmacist in the management of breast cancer were included in the final analysis. No publication date limits were set. A total of 1625 articles were retrieved from the electronic databases, of which 14 met the inclusion criteria. The current scoping review consists of different study types, including randomized controlled trials, cross-sectional studies, pre-post studies, retrospective cohort studies, quality improvement projects, case-control studies, and one pharmacoeconomic study. Pharmacists commonly provided the following interventions: consultations regarding chemotherapy treatment, risk assessment and patient education, adverse drug reactions and drug-drug interactions detection, and adherence assessment. This scoping review highlights the beneficial effects of the involvement of pharmacists in breast cancer management, such as better quality of life, reduced drug interaction risk, greater adherence rates, and improved patient knowledge. This confirms the importance of including the pharmacist in the oncology team caring for patients with breast cancer. Full article
(This article belongs to the Special Issue From Screening to Treatment: Technology’s Impact on Breast Cancer Care)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

32 pages, 2203 KiB  
Guidelines
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting
by Mita Manna, Karen A. Gelmon, Jean-François Boileau, Christine Brezden-Masley, Jeffrey Q. Cao, Katarzyna J. Jerzak, Ipshita Prakash, Sandeep Sehdev, Christine Simmons, Nathaniel Bouganim, Muriel Brackstone, David W. Cescon, Stephen Chia, Ian S. Dayes, Scott Edwards, John Hilton, Anil Abraham Joy, Kara Laing, Marc Webster and Jan-Willem Henning
Curr. Oncol. 2024, 31(11), 6536-6567; https://doi.org/10.3390/curroncol31110484 - 24 Oct 2024
Viewed by 1695
Abstract
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of breast cancer associated with a poor prognosis when sub-optimally treated. Recent advances include new and effective targeted therapies that have significantly improved outcomes for patients. Despite these advances, there [...] Read more.
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of breast cancer associated with a poor prognosis when sub-optimally treated. Recent advances include new and effective targeted therapies that have significantly improved outcomes for patients. Despite these advances, there are significant gaps across Canada, underscoring the need for evidence-based consensus guidance to inform treatment decisions. Addressing these gaps is crucial to ensuring that effective therapies are integrated into clinical practice, so as to improve the lives of patients affected by this aggressive form of breast cancer. The Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance is a standing nucleus committee of clinical-academic oncologists across Canada and Breast Cancer Canada, a patient organization. The mandate of this group is to provide evidence-based guidance on best practices in the management of patients with breast cancer. These consensus recommendations were developed using a modified Delphi process with up to three rounds of anonymous voting. Consensus was defined a priori as ≥75% of voters agreeing with the recommendation as written. There are 9 recommendations in the early setting; 7 recommendations in the metastatic setting; and 10 recommendations for patients with brain metastases. Full article
(This article belongs to the Special Issue From Screening to Treatment: Technology’s Impact on Breast Cancer Care)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop